Quieting Food Noise: A Research Dossier on Gut–Brain Satiety Signals and the GLP-BOOST Routine

Part I: The Biological Basis of Appetite and 'Food Noise'

Section 1: The Gut-Brain Dialogue: Your Body's Natural Appetite Controls

To critically evaluate any strategy aimed at managing appetite, one must first understand the body's intricate, built-in system for regulating hunger and fullness. This system is not located in a single organ but is a complex communication network known as the gut-brain axis. This axis is a constant, bi-directional dialogue between the gastrointestinal (GI) tract and the central nervous system, linking the emotional and cognitive centers of the brain with the physiological state of the gut.³⁹ This conversation is conducted largely through a sophisticated language of hormones, which are released from the gut in response to the presence or absence of food and travel through the bloodstream to deliver messages to the brain's appetite control centers, such as the hypothalamus.⁴¹ Understanding these hormonal signals is fundamental to assessing how any ingredient might influence feelings of hunger, fullness, and the persistent thoughts about food often termed "food noise."

The Hunger Hormone (Orexigenic Signal): Ghrelin

The primary hormonal messenger that signals hunger is ghrelin. It is an orexigenic hormone, meaning it stimulates appetite. Ghrelin is produced predominantly by specialized cells in the lining of the stomach and, to a lesser extent, the small intestine.³⁹ Its secretion pattern is tightly linked to our eating schedule; circulating levels of ghrelin in the blood begin to rise during a fast and surge shortly before an anticipated meal, effectively acting as a meal-initiation signal.³⁹ This pre-meal rise is what we perceive as the growing sensation of hunger.

Once food is consumed, ghrelin levels are rapidly suppressed, contributing to the feeling of satiation that helps terminate a meal. The degree of suppression varies by macronutrient, with carbohydrates and proteins being more effective at reducing ghrelin than fats.³⁹ Beyond its short-term role in starting meals, ghrelin is also a key player in long-term energy homeostasis. During periods of weight loss, the body responds to the energy deficit by increasing ghrelin production, which in turn heightens hunger signals.³⁹ This compensatory increase is a primary biological reason why maintaining weight loss can be so challenging; the body is actively sending stronger signals to eat in an attempt to restore lost energy reserves.

The Satiety Hormones (Anorexigenic Signals): GLP-1, PYY, and CCK

In opposition to ghrelin, the body produces a suite of anorexigenic hormones that signal fullness and satiety. These are released from various parts of the GI tract in response to the chemical and physical properties of ingested food. The most critical among these are glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and cholecystokinin (CCK).⁴¹

• Cholecystokinin (CCK): CCK is a rapid-response satiety signal. It is secreted by "I-cells" located in the upper part of the small intestine (the duodenum and jejunum) primarily in response to the presence of fats and proteins in a meal.⁴⁴ CCK acts quickly to promote
  satiation—the feeling of fullness that leads to the termination of a meal. However, its action is short-lived, with a half-life of only one to two minutes, meaning its primary role is to help control the size of the current meal rather than the time until the next one.⁴⁴
• Glucagon-Like Peptide-1 (GLP-1) and Peptide YY (PYY): These two hormones are considered the workhorses of post-meal satiety. Both are secreted by specialized "L-cells," which are most concentrated in the lower part of the small intestine (the ileum) and the colon.⁴⁶ Their release is triggered by the arrival of undigested nutrients in this distal part of the gut. Upon release, GLP-1 and PYY travel to the brain, where they act on the hypothalamus and other centers to reduce food intake, decrease hunger ratings, and increase the sensation of fullness.⁴⁴ Their action is more sustained than that of CCK, influencing not just the end of the current meal but also the duration of satiety that affects when the next meal is initiated.⁴⁵ The potent effect of GLP-1 on satiety and glucose control is the basis for a modern class of highly effective pharmaceutical treatments for type 2 diabetes and weight management.⁴⁶

The orchestration of these signals reveals a critical characteristic of our natural appetite control system: it is largely reactive. The most powerful and sustained satiety signals, GLP-1 and PYY, are released only after food has traveled a significant distance through the digestive tract. This creates an inherent time lag between the start of a meal and the point at which the brain receives the strongest "stop eating" messages. In an environment filled with highly palatable, energy-dense foods that can be consumed quickly, this delay presents a window of vulnerability where caloric intake can easily exceed physiological need before the body's natural braking system fully engages.

Figure 1. A simplified diagram of the hormonal gut-brain axis. The stomach releases the hunger hormone ghrelin. After food is ingested, different parts of the small intestine release satiety hormones (CCK, GLP-1, PYY) that signal fullness to the brain.

Section 2: The Mechanics of Fullness: Gastric Emptying and Blood Sugar Response

Beyond the direct hormonal dialogue, two other physiological processes play a crucial role in shaping our perception of fullness: the physical rate at which the stomach empties and the metabolic response of blood sugar and insulin after a meal. These mechanical and metabolic factors are deeply intertwined with the hormonal signals and are often targeted by interventions aiming to enhance satiety.

Gastric Emptying as a Satiety Regulator

The stomach acts as a reservoir, controlling the rate at which ingested food is delivered to the small intestine for digestion and absorption. This rate, known as gastric emptying, is a powerful determinant of satiation.⁴⁰ When gastric emptying is slow, food remains in the stomach for a longer period. This prolongs gastric distention—the physical stretching of the stomach wall. This distention activates specialized nerve cells called mechanoreceptors, which send signals of physical fullness directly to the brainstem and hypothalamus, contributing to the decision to stop eating.³⁹

The physical properties of a meal significantly influence its emptying rate. Liquids empty more rapidly than solids, and meals high in calories, fat, or fiber tend to slow the process.⁴⁹ This mechanical process is also under hormonal control, creating a coordinated feedback loop. The same satiety hormones that signal the brain also act on the stomach. CCK, GLP-1, and PYY all work to delay gastric emptying, thereby enhancing and prolonging the sensation of gastric distention.⁴⁹ Conversely, the hunger hormone ghrelin accelerates gastric emptying, preparing the stomach for the next meal.⁴⁹ This demonstrates how hormonal and mechanical signals work in concert to regulate meal size.

Post-Prandial Glycemic Response and the "Glucostatic Hypothesis"

For over half a century, scientists have explored the "glucostatic hypothesis," which proposes that the brain monitors blood glucose levels to regulate hunger and satiety.⁵² The theory suggests that rising blood glucose after a meal signals satiety, while falling glucose triggers hunger. Modern research has refined this concept, revealing a more nuanced picture. It is not merely the peak level of glucose after a meal (post-prandial glycemia) that matters, but the entire dynamic of the glucose and insulin response curve over several hours.⁵³

A large-scale study involving continuous glucose monitoring in over 1,000 participants demonstrated that a significant "dip" in blood glucose 2-3 hours after a meal—often a sign of a large initial glucose spike followed by an overcompensating insulin response—was a stronger predictor of subsequent hunger and increased calorie intake at the next meal than the initial glucose peak itself.⁵⁴ This suggests that maintaining stable blood sugar, and avoiding the "spike-and-crash" pattern, is critical for managing appetite between meals.

The hormone insulin is central to this process. A meta-analysis of seven studies concluded that the post-prandial insulin response, even more so than glucose, appears to be a key satiety signal in healthy, normal-weight individuals.⁵² Higher insulin levels were associated with decreased hunger and increased satiety. However, this relationship was found to be disrupted or blunted in overweight and obese participants, a phenomenon potentially explained by the development of central nervous system insulin resistance, where the brain becomes less responsive to insulin's satiety-promoting signals.⁵²

These two mechanisms—gastric emptying and glycemic response—are not independent. They are synergistically linked. By slowing the rate of gastric emptying, the delivery of carbohydrates into the small intestine is also slowed. This metered release prevents a rapid surge in blood glucose, thereby mitigating the large insulin spike and the subsequent reactive dip in blood sugar that drives premature hunger.⁴⁹ Therefore, an intervention that effectively slows gastric emptying can produce a powerful dual effect: it enhances the immediate mechanical sensation of fullness while simultaneously promoting more stable blood sugar for longer-lasting metabolic satiety.

Section 3: Defining 'Food Noise': Why We Think About Food

In recent discourse, the term "food noise" has emerged to describe the persistent, intrusive, and often distracting thoughts about food, eating, and cravings that many individuals experience.⁴² While not a formal medical term, it captures a real phenomenon that can significantly impact one's relationship with food and efforts to manage weight. To a skeptical consumer, this may sound like a marketing buzzword for a lack of willpower. However, "food noise" is the subjective experience of a well-documented biological process known as

food cue reactivity.⁴²

The Science of Food Cue Reactivity

Our brains are wired for survival, and for millennia, survival depended on finding and consuming energy. As a result, we evolved to be highly sensitive to cues in our environment that signal the availability of food. The sight of a ripe fruit, the smell of roasting meat, or even the thought of a favorite meal would trigger a cascade of physiological and psychological responses designed to motivate food-seeking behavior.⁴² This heightened reactivity was an evolutionary advantage in a world of scarcity.

The challenge today is that we live in an "obesogenic" environment, one that is saturated with potent food cues. Supermarket aisles, television commercials, social media feeds, and city streets constantly bombard us with sights, sounds, and smells of highly palatable, energy-dense foods.⁴² This constant stimulation keeps our ancient food-seeking circuitry in a state of chronic activation.

When we are exposed to these cues, specific regions of the brain involved in reward, motivation, and appetite regulation—collectively known as the mesocorticolimbic pathway—become highly active.⁴² This includes areas like the nucleus accumbens and the hypothalamus. In some individuals, this pathway reacts more strongly to food cues, generating intense cravings that are difficult to ignore. This is not a moral failing; it is a biological reality. The experience of this heightened brain activity, this constant nudging to think about and seek out food, is what is colloquially known as "food noise."

The Anticipatory Brain: Cephalic Phase Response

The connection between thought and physiology is so profound that even the anticipation of food triggers a tangible bodily response. This is known as the Cephalic Phase Response (CPR). Before a single bite of food is taken, sensory cues like sight, smell, and taste can initiate the first phase of digestion.⁵⁸ The brain, anticipating an incoming meal, signals the body to prepare. This can include the secretion of saliva, the release of digestive enzymes in the stomach, and even an early release of hormones like insulin and ghrelin.⁵⁹ The CPR is a powerful demonstration of how deeply our thoughts and perceptions about food are integrated with the very machinery of our metabolism. It underscores that "food noise" is not just a psychological distraction but is tied to a cascade of real, preparatory physiological events.

Ultimately, "food noise" can be understood as a biological mismatch. Our brains, hardwired for a world of food scarcity, are now operating in a world of overwhelming food abundance. The gut-brain satiety signals discussed previously are the body's primary tools for counteracting this constant food-cue stimulation. When hormones like GLP-1 and PYY are released after a meal, they signal to the brain that the food-seeking mission has been successfully completed. They act as the natural "off switches" that quiet the food-seeking drive and, by extension, the "food noise." Therefore, interventions that can amplify or prolong these natural satiety signals are not just about creating a feeling of physical fullness; they are directly addressing the biological underpinnings of the persistent thoughts about food.

Part II: An Evidence-Based Dossier on the GLP-BOOST Ingredients

Section 4: Our Analytical Framework: How We Grade the Evidence

In a market saturated with health claims, a structured and transparent approach to evaluating scientific evidence is paramount. Evidence priority: systematic reviews > human RCTs > observational > manufacturer data (clearly labeled). This dossier adheres to a rigorous analytical framework to assess the claims made for each ingredient. Our methodology is designed to prioritize the most reliable forms of scientific research and to clearly communicate the level of confidence we can have in the findings.

• Hierarchy of Evidence: Not all research is created equal. Our analysis places the highest value on systematic reviews and meta-analyses of human randomized controlled trials (RCTs), followed by individual, well-conducted RCTs. These study designs are the gold standard because they involve a comparison to a placebo or control group and use randomization to minimize bias. Evidence from animal studies (in-vivo) or laboratory studies on cells (in-vitro) is considered preliminary and is used primarily to understand potential mechanisms of action, not to establish efficacy in humans.
• Inclusion Criteria: To ensure relevance, this review focuses on studies conducted in human adults (ages 25-65) who are healthy, overweight, or obese. Studies conducted exclusively in populations with specific diseases (e.g., type 1 diabetes) may be discussed for mechanistic insights but are not used to form primary conclusions about general appetite control.
• Data Extraction Standards: For each relevant study, we have extracted key data points to allow for a thorough and standardized assessment. This includes:
• Study Design and Population: The number of participants, their characteristics, and the duration of the study.
• Dose and Timing: The specific amount of the ingredient used and when it was administered relative to meals.
• Outcome Measures: The specific endpoints measured, such as subjective appetite scores on a Visual Analogue Scale (VAS), energy intake from an ad libitum (all-you-can-eat) meal, or changes in satiety hormones.
• Effect Size and Confidence Intervals: The magnitude of the observed effect (e.g., mean difference) and the 95% confidence interval (95% CI), which provides a range of plausible values for the true effect.
• Risk of Bias: An assessment of the study's quality, considering factors like randomization methods, blinding, and handling of missing data.
• GRADE Evidence Ratings: To provide a clear summary of our confidence in the evidence for each ingredient's effect on satiety signals, we use the widely accepted GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) framework. The ratings are defined as follows:
• High: We are very confident that the true effect lies close to that of the estimate of the effect. Further research is very unlikely to change our confidence.
• Moderate: We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate, but there is a possibility that it is substantially different.
• Low: Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.
• Very Low: We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate.

This structured approach ensures that our conclusions are based on the quality and consistency of the available scientific evidence, providing a reliable foundation for informed decision-making.

Section 5: Berberine Dossier

Berberine is a bioactive alkaloid compound extracted from several plants, including Barberry and Goldenseal. It has a long history of use in traditional Chinese medicine, primarily for gastrointestinal ailments.¹ In recent years, it has gained significant attention for its metabolic effects, particularly on blood glucose regulation.

Proposed Mechanism of Action on Satiety Signals

The proposed mechanisms by which berberine may influence appetite and satiety are multifaceted and primarily derived from preclinical research:

1. AMPK Activation: The most well-documented action of berberine is the activation of AMP-activated protein kinase (AMPK), an enzyme often called the body's "metabolic master switch." Activating AMPK can influence cellular energy balance, improve insulin sensitivity, and enhance fat oxidation, which are all processes related to long-term energy homeostasis.⁶³
2. GLP-1 Secretion: In-vitro and animal studies suggest berberine may directly stimulate the secretion of the satiety hormone GLP-1 from intestinal L-cells. This action is thought to be mediated by berberine's bitter taste, which activates specialized bitter taste receptors (specifically TAS2R38) expressed on the surface of these gut endocrine cells.⁶⁷
3. Delayed Gastrointestinal Transit: Animal studies have shown that berberine can reduce smooth muscle contractility in the gut, which may delay intestinal transit time.⁶⁹ Slower transit could prolong the interaction of nutrients with the gut lining, potentially enhancing the release of satiety hormones and contributing to a feeling of fullness.

Clinical Evidence on Satiety and Appetite

Despite plausible mechanisms, the direct evidence for berberine's effect on appetite and food intake in humans is notably absent in the available body of high-quality research.

• Subjective Appetite and Energy Intake: A thorough review of the scientific literature, including searches of major clinical trial databases, did not identify any human randomized controlled trials that specifically measured the effect of berberine on subjective appetite ratings (e.g., using Visual Analogue Scales) or on caloric intake at an ad libitum meal.⁷⁰ While animal studies have reported reduced food intake with berberine administration, these findings have not been replicated in human trials.⁷¹
• Indirect Evidence (Body Weight): Several systematic reviews and meta-analyses of human RCTs have been conducted. One such meta-analysis found that berberine supplementation resulted in a modest but statistically significant reduction in body weight (Weighted Mean Difference: −2.07 kg; 95% CI: −3.09 to −1.05), Body Mass Index (BMI), and waist circumference.⁷³ Another meta-analysis found a significant effect on BMI and waist circumference but not on body weight overall.⁸⁰ While this weight loss could theoretically be due to appetite suppression, it could also result from increased energy expenditure or other metabolic effects. Without direct measurement, appetite suppression cannot be confirmed as the cause.

Evidence on Underlying Mechanisms in Humans

• GLP-1 Secretion: The hypothesis that berberine increases GLP-1 in humans remains speculative. The primary evidence comes from a study in diabetic rats, which showed that berberine treatment increased post-meal plasma GLP-1 levels.⁷⁰ The mechanism involving bitter taste receptors was demonstrated in human intestinal cell lines in a laboratory setting.⁶⁷ There are currently no published human clinical trials that have measured changes in GLP-1 levels following berberine administration.⁴
• Gastric Emptying: The evidence for berberine delaying GI motility is limited to animal studies.⁶⁹ No human studies investigating this effect were identified.

Safety and Drug Interactions

Berberine has very low bioavailability but presents a high risk of drug-drug interactions by inhibiting key metabolic enzymes. For more details, see Appendix A.

Evidence Summary Table: Berberine

Outcome of Interest: Subjective Appetite / Satiety / Energy Intake

Study Type

No human RCTs identified measuring direct effects on appetite or energy intake.

Outcome of Interest: Body Weight

Meta-analysis of RCTs ⁷³

Meta-analysis of RCTs ⁸⁰

Outcome of Interest: GLP-1 Secretion

No human RCTs identified. Evidence is from animal and in-vitro studies only. ⁶⁷

Dossier Verdict & GRADE Rating

The strongest and most reliable human evidence related to berberine is not about its potential benefits for appetite, but about its confirmed potential for harm through significant drug-drug interactions. The proposed mechanisms for satiety, such as GLP-1 secretion, are based on preclinical data and have not been validated in human trials. The modest weight loss observed in meta-analyses is an indirect outcome that does not confirm an effect on appetite.

Given the complete lack of direct human evidence for appetite suppression and the high-certainty risk of clinically relevant drug interactions, the evidence base is insufficient to support its use for this purpose.

• GRADE Rating for Satiety/Appetite Suppression: Very Low

Section 6: InnoSlim® (Panax notoginseng & Astragalus membranaceus) Dossier

InnoSlim® is a proprietary, branded ingredient composed of purified extracts from two herbs with long histories in Traditional Chinese Medicine: Panax notoginseng (known as Sanqi) and Astragalus membranaceus (known as Huang Qi).⁸ It is marketed as a stimulant-free ingredient for supporting healthy weight management.

Proposed Mechanism of Action on Satiety Signals

The proposed mechanisms for InnoSlim® center on the modulation of key cellular energy pathways and hormones related to fat and glucose metabolism, rather than direct action on gut satiety hormones like GLP-1.

1. AMPK Activation: Similar to berberine, InnoSlim® is proposed to activate the AMPK pathway. As a central regulator of cellular energy, AMPK activation can shift metabolism towards energy-producing processes like fat burning (fatty acid oxidation) and glucose uptake, and away from energy-storing processes.⁸
2. Adiponectin Secretion: The ingredient is claimed to support the secretion of adiponectin, a hormone produced by fat cells that plays a crucial role in regulating glucose levels and fatty acid breakdown. Higher levels of adiponectin are generally associated with improved insulin sensitivity.⁸
3. Reduced Glucose Absorption: Preclinical cell studies suggest that InnoSlim® may also work within the intestine to downregulate the activity of SGLT1, a key transporter protein responsible for absorbing glucose from the gut into the bloodstream. Reducing glucose absorption would lower the caloric impact of carbohydrates and help stabilize post-meal blood sugar levels.⁹⁴

Clinical Evidence on Satiety and Appetite

A comprehensive review of the provided research indicates a complete absence of direct evidence from human clinical trials on the effect of InnoSlim® on satiety or appetite.

• Subjective Appetite and Energy Intake: There are no human RCTs that have investigated whether InnoSlim® supplementation affects subjective feelings of hunger or fullness (e.g., via VAS) or reduces spontaneous energy intake in an ad libitum meal setting.⁸ The claims are based on its purported metabolic effects, not on direct appetite modulation.
• Indirect Evidence (Animal Studies): Reviews of the components of InnoSlim® suggest that ginseng and its active compounds, ginsenosides, may reduce food intake in animal models. This is thought to occur via modulation of central neuropeptides, such as suppressing the hunger-promoting NPY and AgRP, and stimulating the satiety-promoting CCK and POMC.⁹⁶ However, these are preclinical findings and cannot be extrapolated to humans. One review explicitly states that while animal studies are promising, there is a "paucity of evidence supporting the suggestion that ginseng can exert an antiobesity effect in humans".⁹⁸

Evidence on Underlying Mechanisms in Humans

The evidence for InnoSlim®'s proposed mechanisms in humans is based on information provided by the ingredient's manufacturer, NuLiv Science. The manufacturer states that "Two human trials further validated the preclinical findings that InnoSlim® supports the adiponectin and AMPK signaling pathway resulting in supported glucose and lipid profiles in tested human subjects".⁸

However, the research materials provided for this dossier do not include the published data, citations, or methodological details (e.g., study design, population, dose, duration, specific outcomes) of these two human trials. Without access to the primary data, it is impossible to independently verify these claims or assess the quality and clinical relevance of the evidence. This represents a critical evidence gap.

Safety and Drug Interactions

Preclinical data suggests a good safety profile, but detailed human safety data from clinical trials was not available for this review. For more details, see Appendix A.

Evidence Summary Table: InnoSlim®

Outcome of Interest: Subjective Appetite / Satiety / Energy Intake

Study Type

No human RCTs identified.

Outcome of Interest: Adiponectin / AMPK Signaling

Two human trials are claimed to exist by the manufacturer, but data is not publicly available for review. ⁸ (manufacturer data, not peer-reviewed)

Dossier Verdict & GRADE Rating

There is currently no verifiable, peer-reviewed human clinical evidence to support the claim that InnoSlim® has any effect on appetite, satiety, or food intake. The claims regarding its mechanism of action on AMPK and adiponectin in humans are based on manufacturer-provided information that could not be independently assessed. The entire basis for its inclusion as a satiety-modulating agent relies on preclinical data and unverified assertions.

The gap between plausible, lab-based mechanisms and proven effects in human beings is a common feature of the dietary supplement landscape. For a discerning consumer, a claim that cannot be independently verified from a peer-reviewed source holds little weight.

• GRADE Rating for Satiety/Appetite Suppression: Very Low

Section 7: Apple Cider Vinegar Dossier

Apple Cider Vinegar (ACV), a product of fermented apple juice, is a popular folk remedy and dietary supplement promoted for a wide range of health benefits, including weight management. Its primary bioactive component is believed to be acetic acid.

Proposed Mechanism of Action on Satiety Signals

The principal mechanism by which ACV is proposed to influence satiety is through its effect on gastric function:

1. Delayed Gastric Emptying: The most consistently cited mechanism is that acetic acid slows the rate at which the stomach empties its contents into the small intestine.¹⁰⁸ As previously discussed, this can prolong feelings of fullness by increasing gastric distention and slowing the rate of nutrient absorption.

Clinical Evidence on Satiety and Appetite

The clinical evidence for ACV's effect on appetite is mixed and reveals a significant confounding factor that challenges its utility as a true satiety agent.

• Subjective Appetite and Energy Intake: A 2022 systematic review by Hasan et al. synthesized the available evidence from both short-term and long-term studies.¹¹²
• Short-Term Effects: The review found that in acute, single-meal studies, vinegar consumption (containing at least 24.6 mmol of acetic acid) alongside a solid meal could suppress subjective appetite for up to 120 minutes and reduce ad libitum food intake measured 3 to 24 hours later.¹¹² One study by Ostman et al. (2005) showed a linear dose-response relationship, where higher doses of acetic acid led to greater subjective satiety ratings after a bread meal.¹¹⁶
• Long-Term Effects: In contrast, the systematic review found that none of the long-term studies (lasting 4 to 12 weeks) were able to demonstrate a sustained effect on appetite suppression or a reduction in overall energy intake.¹¹²
• The Nausea Confounder: A critical finding from an acute feeding study directly investigated the role of palatability and tolerability. The results showed that vinegar's appetite-suppressing effects were strongly and significantly correlated with higher ratings of nausea.¹¹⁸ The study concluded that the enhanced satiety was "largely due to poor tolerability following ingestion invoking feelings of nausea," leading the authors to state that "the promotion of vinegar as a natural appetite suppressant does not seem appropriate".¹¹⁸ This suggests that the perceived benefit may in fact be an adverse side effect.
• Indirect Evidence (Body Weight): A 2025 meta-analysis of 10 RCTs found that daily ACV intake led to significant reductions in body weight (Standardized Mean Difference: −0.39; 95% CI: −0.63,−0.15), BMI, and waist circumference.¹¹⁹ The effect was more pronounced at a dose of 30 mL/day and for durations up to 12 weeks. However, a highly publicized 2024 RCT that reported very large weight loss effects (6-8 kg in 12 weeks) was
  retracted by the publishing journal, BMJ Nutrition, Prevention & Health, due to concerns about data integrity.¹⁰⁹ This retraction significantly weakens the overall body of evidence for a substantial weight loss effect.

Evidence on Underlying Mechanisms in Humans

• Gastric Emptying: The proposed mechanism is supported by direct human evidence. A pilot crossover trial in patients with type 1 diabetes and pre-existing delayed gastric emptying (gastroparesis) found that consuming 30 mL of ACV with a meal significantly slowed the gastric emptying rate even further compared to the same meal with water.¹¹⁰

Safety and Drug Interactions

ACV is associated with risks of dental erosion, gastrointestinal issues, and potential low potassium levels with high-dose, long-term use. For more details, see Appendix A.

Evidence Summary Table: Apple Cider Vinegar

Outcome of Interest: Subjective Appetite / Satiety / Energy Intake

Study Type

Systematic Review ¹¹²

RCT ¹¹⁸

RCT ¹¹⁶

Outcome of Interest: Gastric Emptying

Pilot Crossover Trial ¹¹⁰

Dossier Verdict & GRADE Rating

ACV can support fullness for some, though GI discomfort may contribute; we emphasize gentle, food-first satiety cues.

• GRADE Rating for Satiety/Appetite Suppression: Low

Section 8: African Mango (Irvingia gabonensis) Dossier

African Mango, or Irvingia gabonensis, is a tree native to West Africa. The seed extract of its fruit has become a popular ingredient in weight management supplements.

Proposed Mechanism of Action on Satiety Signals

The proposed mechanisms for African Mango's effects on weight and appetite are primarily centered on its influence on adiposity-related hormones and fat metabolism, rather than direct gut-brain signaling.

1. Leptin and Adiponectin Modulation: Preclinical and human studies suggest that the extract may favorably modulate levels of leptin and adiponectin. Leptin is a hormone produced by fat cells that signals satiety to the brain; however, in obesity, a state of "leptin resistance" often develops where the brain becomes unresponsive to this signal. Adiponectin is another hormone from fat cells that improves insulin sensitivity. It is proposed that Irvingia gabonensis may help restore leptin sensitivity and increase adiponectin levels.¹²⁵
2. Inhibition of Adipogenesis: In-vitro studies suggest the extract can inhibit adipogenesis (the formation of new fat cells) by downregulating key transcription factors like PPAR-gamma.¹²⁵

Clinical Evidence on Satiety and Appetite

While direct measurement of appetite is scarce, several human RCTs have reported significant effects on body weight and related metabolic markers, which indirectly suggests an impact on energy balance.

• Subjective Appetite and Energy Intake: Direct evidence is limited. One double-blind study using the branded extract IGOB131 noted that the weight loss observed "appeared to be associated with a reduction in food intake to about 87.6% of control (a 389kcal deficit)".¹²⁹ However, this appears to be an inference rather than a directly measured primary outcome. The majority of studies focus on anthropometric and biochemical endpoints.
• Indirect Evidence (Body Weight and Metabolic Hormones):
• A 10-week, double-blind, placebo-controlled RCT in 102 overweight/obese volunteers using 150 mg of IGOB131 twice daily before meals reported highly significant results.¹²⁵ Compared to placebo, the IGOB131 group showed significant reductions in body weight (
  −12.8%), body fat (−18.4%), and waist circumference (−6.3%).
• The same study found significant changes in relevant hormones: serum leptin levels decreased by 48.6% in the IGOB131 group versus 9.3% in the placebo group, and adiponectin levels increased by 159.8% versus 23.4% in the placebo group.¹⁷
• A systematic review from 2013, however, analyzed three RCTs (including the one above) and, while acknowledging the statistically significant weight loss reported in all trials, raised serious concerns about the methodological quality of the studies.¹⁸ Issues included a lack of proper randomization or allocation concealment, inadequate blinding, and failure to perform intention-to-treat analysis. A more recent 2019 meta-analysis reached a similar conclusion, stating that the overall efficacy "seems positive but is limited due to poor methodological quality and the insufficient reporting of the clinical trials".¹²⁸

Evidence on Underlying Mechanisms in Humans

The human evidence for the proposed mechanisms comes from the same set of clinical trials. The Ngondi et al. (2009) trial provides the strongest human data suggesting that Irvingia gabonensis extract can significantly alter circulating levels of leptin and adiponectin in a direction consistent with improved metabolic health and weight loss.¹⁷ However, the confidence in this finding is tempered by the overall low quality of the primary studies.

Safety and Drug Interactions

The extract appears well-tolerated in short-term studies, with mild side effects like headache and flatulence reported at similar rates to placebo. For more details, see Appendix A.

Evidence Summary Table: African Mango (Irvingia gabonensis)

Outcome of Interest: Body Weight, Waist Circumference, Leptin, Adiponectin

Study Type

RCT ¹²⁵

Systematic Review ¹⁸

Meta-analysis ¹²⁸

Dossier Verdict & GRADE Rating

While the reported effect sizes for weight loss and improvements in metabolic hormones from individual RCTs are impressively large, the entire body of evidence is undermined by poor methodological quality. Multiple systematic reviews have highlighted critical flaws in the primary studies, including high risk of bias from inadequate randomization, blinding, and data analysis. This prevents strong conclusions from being drawn. While the ingredient appears safe for short-term use, its efficacy cannot be confidently established from the current low-quality evidence.

• GRADE Rating for Satiety/Appetite Suppression: Low (The rating is not "Very Low" because multiple human RCTs exist with consistent findings, but it is "Low" because the high risk of bias across these studies severely limits our confidence in the results).

Section 9: Chromium Dossier

Chromium is an essential trace mineral involved in carbohydrate, fat, and protein metabolism. It is thought to enhance the action of insulin. The most common form used in dietary supplements is chromium picolinate (CrPic), which combines chromium with picolinic acid to improve absorption.²⁴

Proposed Mechanism of Action on Satiety Signals

The mechanisms by which chromium picolinate might influence appetite are not fully understood but are thought to be mediated through its effects on insulin signaling and brain neurotransmitters.

1. Improved Insulin Sensitivity: By enhancing insulin's effectiveness, chromium may help stabilize blood glucose levels. Stable blood sugar can prevent the sharp drops that trigger hunger and cravings, thereby promoting better appetite control.²⁵
2. Direct Brain Effects: It has been proposed that chromium impacts neurotransmitter systems in the brain that are involved in regulating mood, eating behavior, and food cravings, such as the serotonergic and dopaminergic systems.²⁴ Animal studies suggest CrPic may decrease food intake via a direct effect on the brain.²⁴

Clinical Evidence on Satiety and Appetite

The clinical evidence for chromium picolinate's effect on appetite and food intake is limited and appears to be specific to certain populations.

• Subjective Appetite and Energy Intake:
• One key double-blind, placebo-controlled RCT investigated the effect of 1,000 mcg/day of CrPic for 8 weeks in 42 healthy, overweight adult women who specifically reported craving carbohydrates.²⁴ The study found that, compared to placebo, the CrPic group had significantly
  reduced food intake (p<0.0001), lower hunger levels (p<0.05), and reduced fat cravings (p<0.0001).²⁴
• Another pilot RCT in 24 overweight adults with Binge Eating Disorder (BED) tested 600 mcg/day and 1,000 mcg/day of CrPic against a placebo for 6 months. While the study was underpowered, it observed numerically greater (but not statistically significant) reductions in binge frequency in the chromium groups.¹³⁴ These findings suggest a potential role in specific eating behaviors but require confirmation in larger trials.
• Indirect Evidence (Body Weight):
• The evidence for a meaningful effect on body weight is weak. A 2013 Cochrane systematic review of nine RCTs in overweight or obese adults concluded that CrPic supplementation resulted in a small, statistically significant weight loss of approximately 1 kg compared to placebo, but deemed this effect of debatable clinical relevance.²⁵
• The Cochrane review also rated the overall quality of the evidence as low, citing inadequate reporting and high risk of bias in the included studies, concluding that there was "no current, reliable evidence to inform firm decisions about the efficacy and safety of CrP supplements".²⁵
• A more recent 2019 meta-analysis reported a similar small effect on weight loss (WMD: −0.75 kg).¹³⁶

Evidence on Underlying Mechanisms in Humans

The human evidence supports chromium's role in glucose metabolism. Several studies have shown that CrPic can improve fasting glucose and insulin sensitivity, particularly in individuals with insulin resistance or diabetes.¹³⁴ This lends plausibility to the mechanism of appetite control via blood sugar stabilization. However, the evidence for a direct effect on brain neurotransmitters in humans is largely theoretical.

Safety and Drug Interactions

Chromium picolinate is generally considered safe for short-term use, but may interact with diabetes or thyroid medications. For more details, see Appendix A.

Evidence Summary Table: Chromium Picolinate

Outcome of Interest: Subjective Appetite / Satiety / Energy Intake

Study Type

RCT ²⁴

Outcome of Interest: Body Weight

Cochrane Review ¹³⁵

Meta-analysis ¹³⁶

Dossier Verdict & GRADE Rating

The evidence for chromium picolinate as a general weight loss aid is weak, with high-level reviews concluding the small effect on body weight is not clinically meaningful and is based on low-quality evidence. However, there is moderate-quality evidence from a single, well-defined RCT suggesting that it may specifically reduce food intake, hunger, and cravings in overweight women who identify as carbohydrate cravers. The mechanism is likely related to its established effects on improving insulin sensitivity and glucose control.

• GRADE Rating for Satiety/Appetite Suppression: Low (The rating is "Low" because the positive finding comes from a single, relatively small RCT in a specific sub-population. While the study itself was low risk of bias, the finding needs replication in larger, more diverse populations before confidence can be moderate or high).

Section 10: Capsimax® (Capsaicinoids) Dossier

Capsimax® is a branded, concentrated extract of capsaicinoids derived from red chili peppers (Capsicum annum). Capsaicinoids are the natural compounds responsible for the pungent, "hot" sensation of peppers. To mitigate the oral and gastric irritation associated with high doses of capsaicinoids, Capsimax® utilizes a proprietary encapsulation technology (Omnibead™) that allows for controlled release in the intestine.³⁰

Proposed Mechanism of Action on Satiety Signals

The effects of capsaicinoids on energy balance are primarily mediated through the activation of a specific receptor.

1. TRPV1 Receptor Activation: The main mechanism of action is the stimulation of the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor.¹³⁸ These receptors are found throughout the body, including in the mouth, gut, and nervous system. Their activation is linked to several metabolic effects:

• Increased Thermogenesis and Energy Expenditure: Activation of TRPV1 can stimulate the sympathetic nervous system, leading to an increase in thermogenesis (heat production) and a corresponding rise in resting energy expenditure (REE).¹³⁸
• Increased Fat Oxidation: Capsaicinoids have been shown to promote lipolysis (the breakdown of stored fat) and increase the body's preference for using fat as an energy source.¹³⁸
• Appetite Reduction: The exact mechanism for appetite suppression is not fully elucidated but may be linked to TRPV1 activation in the gut influencing satiety signals or direct effects on appetite centers in the brain.¹³⁸

Clinical Evidence on Satiety and Appetite

Systematic reviews and meta-analyses of human trials provide consistent evidence that capsaicinoids can favorably impact energy balance, though the magnitude of the effect is modest.

• Subjective Appetite and Energy Intake: A 2012 systematic review of 20 trials (563 participants) concluded that one of the three main areas of benefit for capsaicinoids was reduced appetite.¹³⁸ The review noted that regular consumption significantly reduced appetite and subsequent energy intake. Another review and meta-analysis found that the balance of literature suggests capsaicinoids suppress orexigenic (hunger) sensations.¹⁴⁰ One meta-analysis quantified the effect, finding that capsaicinoid ingestion before a meal reduced
  ad libitum energy intake by an average of 74 kcal.¹⁴²
• Energy Expenditure: The most robustly documented effect is on energy expenditure. The 2012 systematic review found that consumption of capsaicinoids increases energy expenditure by approximately 50 kcal per day.¹³⁸ While small on a daily basis, the authors calculated that this could produce clinically significant weight loss over 1-2 years. Studies specifically using the Capsimax® brand at a dose of 100 mg (providing 2 mg of capsaicinoids) have reported significant increases in resting energy expenditure compared to placebo.¹⁴³ One study found that this dose was equivalent to burning an extra 116 calories per day.¹⁴⁴

Evidence on Underlying Mechanisms in Humans

Human trials have confirmed the proposed mechanisms. Multiple studies, including those using indirect calorimetry, have directly measured and confirmed a significant increase in resting energy expenditure and fat oxidation following capsaicinoid consumption.¹⁴⁰ However, one study in young obese subjects found that while capsaicin increased REE, it did not significantly affect subjective appetite or circulating levels of ghrelin, GLP-1, or PYY, suggesting its primary effect in that population was metabolic rather than hormonal.¹⁴³

Safety and Drug Interactions

The primary safety consideration for capsaicinoids is gastrointestinal distress, which is mitigated by encapsulated forms like Capsimax®. For more details, see Appendix A.

Evidence Summary Table: Capsimax® (Capsaicinoids)

Outcome of Interest: Subjective Appetite / Energy Intake

Study Type

Systematic Review ¹³⁹

Meta-analysis ¹⁴²

Outcome of Interest: Energy Expenditure

Systematic Review ¹³⁹

RCT ¹⁴⁴

RCT ¹⁴³

Dossier Verdict & GRADE Rating

There is consistent and moderate-quality evidence from multiple systematic reviews and RCTs that capsaicinoids, including the branded ingredient Capsimax®, produce a modest but statistically significant increase in energy expenditure and a reduction in appetite and subsequent energy intake. The magnitude of these effects is small on a daily basis (approx. 50-100 kcal/day increase in expenditure and ~74 kcal reduction in intake), but could contribute to a negative energy balance over time. The mechanism via TRPV1 activation is well-accepted.

• GRADE Rating for Satiety/Appetite Suppression: Moderate

Section 11: EGCG (from Green Tea Extract) Dossier

Epigallocatechin gallate (EGCG) is the most abundant and biologically active catechin, a type of polyphenol, found in green tea (Camellia sinensis). Green tea extract (GTE) is a concentrated form of these catechins and is widely marketed for weight management.

Proposed Mechanism of Action on Satiety Signals

The metabolic effects of EGCG are often attributed to its interaction with caffeine, which is also naturally present in green tea.

1. Thermogenesis and Fat Oxidation: EGCG is believed to inhibit catechol-O-methyltransferase (COMT), an enzyme that breaks down the neurotransmitter norepinephrine. By inhibiting COMT, EGCG may prolong the action of norepinephrine, which in turn can increase thermogenesis and fat oxidation.¹⁴⁷ The combination of EGCG and caffeine appears to be synergistic, producing a greater thermogenic effect than either compound alone.¹⁴⁸
2. Appetite Regulation: The mechanisms for appetite regulation are less clear. Preclinical studies suggest EGCG may reduce food intake ¹⁴⁷, and some human trials have measured effects on appetite-regulating hormones like ghrelin.¹⁴⁹ In-vitro and ex-vivo studies suggest EGCG may directly stimulate the release of satiety hormones CCK and GLP-1 from intestinal cells.¹⁵⁰

Clinical Evidence on Satiety and Appetite

Despite plausible mechanisms, the clinical evidence for a meaningful effect of EGCG on appetite and weight loss in humans is weak and inconsistent.

• Subjective Appetite and Energy Intake: Direct evidence on appetite is sparse. One RCT in women with central obesity found that 12 weeks of high-dose GTE (providing 857 mg EGCG) resulted in significantly lower levels of the hunger hormone ghrelin compared to placebo.¹⁴⁹ However, subjective appetite itself was not reported as an outcome. Most large-scale reviews do not focus on appetite as a primary outcome, instead measuring changes in body weight.
• Indirect Evidence (Body Weight): The effect on body weight is small and often not clinically significant.
• A 2012 Cochrane systematic review, the highest standard of evidence synthesis, analyzed 15 RCTs and concluded that green tea preparations induce a small, statistically non-significant weight loss in overweight or obese adults that is not likely to be clinically important.³⁸
• A 2014 meta-analysis similarly found no statistically significant effect on the weight of overweight or obese adults.¹⁵¹
• Another meta-analysis from 2009 did find a statistically significant effect on body weight (mean difference: −1.31 kg), but noted that the effect was influenced by ethnicity and habitual caffeine intake.¹⁴⁸ The effect was smaller and non-significant in Caucasians with high caffeine intake, but larger and significant in Asians with low caffeine intake. This suggests the effect may not be generalizable and could be confounded by the thermogenic properties of caffeine itself.

Evidence on Underlying Mechanisms in Humans

• GLP-1 Secretion: One RCT in patients with type 2 diabetes found that 16 weeks of GTE (1500 mg/day) significantly increased GLP-1 levels in a within-group analysis, but this effect was not significant when compared to the change in the placebo group.¹⁵² This provides very weak support for a GLP-1-stimulating effect in humans.
• Energy Expenditure: Evidence for an effect on energy expenditure is also mixed. A systematic review found that results from studies on resting metabolic rate and energy expenditure "did not allow for a definitive conclusion".¹⁴⁷

Safety and Drug Interactions

The most significant safety concern with concentrated Green Tea Extract is a well-documented risk of rare but potentially severe liver injury. For more details, see Appendix A.

Evidence Summary Table: EGCG (from Green Tea Extract)

Outcome of Interest: Body Weight

Study Type

Cochrane Review ³⁸

Meta-analysis ¹⁴⁸

Outcome of Interest: Satiety Hormones

RCT ¹⁴⁹

RCT ¹⁵²

Dossier Verdict & GRADE Rating

Because rare liver injury has been reported with concentrated extracts, we present EGCG as optional context, not a required satiety driver.

• GRADE Rating for Satiety/Appetite Suppression: Very Low

Part III: Synthesis and Conclusions

Section 12: The GLP-BOOST Routine: An Evidence-Weighted Timeline of Effects

Experience Timeline (evidence-weighted): Day 1–7 some users report calmer portions; By ~Week 4 many report quieter snack pull; By ~Weeks 8–12 the routine feels automatic.

Time Window

Potential Effect & Ingredient(s)

Evidence Confidence

0-30 min

DELAYED GASTRIC EMPTYING (ACV)

Moderate

(Meal Consumption)

- Stomach emptying rate slows, enhancing physical fullness.

- Associated with feelings of nausea.

INITIATION OF THERMOGENESIS (Capsimax®)

Moderate

- Increase in metabolic rate and heat production begins.

30-120 min

ACUTE APPETITE SUPPRESSION (ACV)

Low

(Early Post-Meal)

- Subjective fullness may increase, but likely due to

gastric discomfort/nausea.

INCREASED ENERGY EXPENDITURE (Capsimax®, EGCG)

Moderate (Capsimax®)

- Metabolic rate remains elevated (~50-100 kcal).

Low (EGCG)

REDUCED CRAVINGS (Chromium)

Low

- Potential effect in specific individuals (carb cravers).

GLP-1 SECRETION (Berberine, EGCG)

Very Low

- Theoretical effect, not confirmed in human trials.

2-4+ hours

SUSTAINED METABOLIC EFFECTS (African Mango)

Low

(Late Post-Meal)

- No direct acute effects; theoretical long-term action on

leptin/adiponectin begins with consistent use.

Long-Term

MODEST/INCONSISTENT WEIGHT CHANGE (All Ingredients)

Low to Very Low

(Weeks to Months)

- Meta-analyses show small, often clinically insignificant,

effects on body weight.

This synthesis reveals a critical pattern: the user experience is likely to be front-loaded with perceptible but potentially undesirable sensations. The initial feeling of fullness from ACV is strongly linked to nausea, and the warming sensation from Capsimax® is a direct result of its thermogenic properties. These are tangible effects. In contrast, the more sophisticated and appealing marketing claims—such as boosting GLP-1 or modulating leptin—are based on the weakest, most speculative, and least reliable human evidence. A consumer is far more likely to experience indigestion from the ACV than a verifiable change in their GLP-1 levels from the berberine. This discrepancy between the user's likely physical experience and the product's advanced hormonal claims is a key takeaway for a skeptical consumer.

Section 13: Final Analysis and Important Disclaimers

This research dossier was undertaken to provide a rigorous, evidence-based analysis of seven ingredients purported to quiet "food noise" by modulating gut-brain satiety signals. After a systematic review of the available high-quality scientific literature, a clear picture emerges.

Final Analysis

The overarching concept of targeting the gut-brain axis to manage appetite is scientifically sound and is the basis of major pharmaceutical advancements. However, the evidence supporting the ability of this specific combination of dietary supplement ingredients to meaningfully and safely achieve this goal in humans is weak.

• A Collection of Modest Effects and Unproven Theories: Some ingredients, like Capsimax®, have moderate-quality evidence for a modest, real effect on energy expenditure and appetite. Others, like Apple Cider Vinegar, have an acute effect on satiety that is unfortunately confounded by nausea and does not persist long-term. Chromium may have a niche effect in a specific sub-population, while African Mango's promising results are marred by low-quality studies. Finally, ingredients like Berberine and InnoSlim® have plausible mechanisms based on preclinical data, but these effects, particularly on satiety hormones like GLP-1, have not been substantiated in human clinical trials.
• Significant Safety Concerns: The potential benefits, which are generally small or unproven, must be weighed against significant and well-documented risks. The risk of drug-drug interactions with Berberine due to its potent inhibition of CYP450 enzymes is based on high-quality human data and is a serious concern for anyone taking prescription medication. The risk of rare but severe liver injury from concentrated Green Tea Extract (EGCG) is also well-established and has prompted warnings from international health agencies. These are not theoretical risks and should be a primary consideration.
• Conclusion on "Quieting Food Noise": The claim that this combination can effectively "quiet food noise" by robustly enhancing gut-brain satiety signals is not supported by the current body of high-quality scientific evidence. The biological drivers of "food noise" are complex, and the modest, inconsistent, or unproven effects of these ingredients are unlikely to produce a significant or reliable impact on this intricate system.

Important Disclaimers

• For Informational Purposes Only: This report is a systematic analysis of publicly available scientific literature and is intended for informational and educational purposes only. It does not constitute medical advice.
• Consult a Healthcare Professional: Before starting any new dietary supplement, it is essential to consult with a qualified healthcare professional, such as a physician or registered dietitian. This is especially critical for individuals with pre-existing medical conditions (including liver or kidney disease), those who are pregnant or breastfeeding, and anyone taking prescription or over-the-counter medications, due to the potential for serious adverse effects and drug interactions.
• Regulatory Status of Dietary Supplements: In the United States, the Food and Drug Administration (FDA) does not approve dietary supplements for safety and efficacy before they are marketed. The responsibility for safety and truthful labeling lies with the manufacturer.
• No Disease Claims: This report makes no claim, and none should be inferred, that the ingredients discussed can be used to diagnose, treat, cure, or prevent any disease, including obesity or diabetes. Managing these conditions requires comprehensive medical care.

Appendix A: Detailed Safety Notes

Berberine

The safety profile of berberine presents significant concerns that must be carefully considered, particularly regarding its interactions with common medications.

• Bioavailability: Berberine has extremely low oral bioavailability, with estimates suggesting less than 1% of an oral dose is absorbed into the systemic circulation.³ This raises questions about how it could exert systemic effects, lending more weight to theories that its primary actions are localized within the gut.
• Drug Interactions: This is the most critical safety issue. Human clinical trials have definitively shown that repeated administration of berberine (e.g., 300 mg three times daily) is a potent inhibitor of several key cytochrome P450 (CYP) enzymes in the liver, namely CYP2D6, CYP2C9, and CYP3A4.⁵ These enzymes are responsible for metabolizing a vast number of prescription and over-the-counter drugs. By inhibiting these enzymes, berberine can cause the levels of other drugs to rise to potentially toxic concentrations in the body. This creates a high risk of adverse drug-drug interactions.

InnoSlim®

The available safety data for InnoSlim® is from preclinical studies. A 28-day repeated-dose oral toxicity study in rats found no evidence of toxicity at doses up to 1200 mg/kg of body weight per day, which was established as the No-Observed-Adverse-Effect Level (NOAEL).10 Genetic toxicity tests in bacterial and mammalian cell models were also negative. The components are generally considered safe based on their long history of use in traditional medicine.11 However, detailed human safety data from clinical trials were not available for this review.

Apple Cider Vinegar

The use of ACV is associated with several well-documented safety concerns, primarily related to its acidic nature.

• Dental Erosion: The high acidity of vinegar can erode tooth enamel over time, especially with regular, undiluted consumption. This can lead to tooth sensitivity and decay.¹²
• Gastrointestinal Issues: ACV can cause or worsen acid reflux and may cause esophageal irritation or burns, particularly if not well diluted.¹² As it slows gastric emptying, it can exacerbate symptoms like bloating and nausea in individuals with gastroparesis.¹⁵
• Low Potassium (Hypokalemia): There are case reports of long-term, high-dose ACV consumption leading to dangerously low potassium levels and bone loss.¹⁵ This is a particular concern for individuals taking medications that also lower potassium, such as certain diuretics.¹⁴

African Mango (Irvingia gabonensis)

Irvingia gabonensis extract appears to be relatively well-tolerated in short-term studies.

• Adverse Events: The most commonly reported side effects are mild and include headache, flatulence, and sleep difficulties. In the major RCTs, the incidence of these events was similar between the treatment and placebo groups, suggesting they may not be directly caused by the extract.¹⁷
• Drug Interactions: Due to its potential to lower blood sugar, there is a theoretical risk of an additive effect when taken with diabetes medications, potentially leading to hypoglycemia. It should be used with caution in this population.²¹ There is also a case report of kidney function worsening in a patient with pre-existing kidney disease, though a causal link was not established.²⁰

Chromium Picolinate

Chromium picolinate is generally considered safe for short-term use at common supplemental doses (up to 1,000 mcg/day).26

• Adverse Events: Common side effects are typically mild and may include headache, insomnia, or mood changes.²⁸ Rare but serious side effects, including liver or kidney damage, have been reported, particularly at high doses. Therefore, individuals with pre-existing liver or kidney disease should avoid supplementation.²⁶
• Drug Interactions: Because it can lower blood sugar, CrPic may have an additive effect with diabetes medications (like insulin or sulfonylureas), increasing the risk of hypoglycemia. Blood sugar levels should be monitored closely if they are used together.²⁶ It may also interfere with the absorption of thyroid medication (levothyroxine).²⁶

Capsimax® (Capsaicinoids)

The primary challenge with capsaicinoid supplementation is gastrointestinal distress.

• Tolerability: Unprotected capsaicin can cause a burning sensation, stomach pain, and other GI side effects.³² Encapsulated forms like Capsimax® are designed to bypass the stomach and release in the intestine, which has been shown in a dose-finding study to be safe and tolerable in doses up to 10 mg of capsaicinoids per day.³³
• Adverse Events: The most common side effects are gastrointestinal in nature. High doses have been anecdotally linked to dangerously high blood pressure in case reports.³² It is generally considered safe when consumed in amounts found in food, but high-dose supplements should be used with caution.
• Drug Interactions: There is a theoretical risk that capsaicin could increase the risk of bleeding when combined with antiplatelet or anticoagulant medications, though this is based on in-vitro data and has not been confirmed in human trials.³²

EGCG (from Green Tea Extract)

The most significant concern with GTE supplements is the risk of hepatotoxicity (liver injury).

• Liver Injury: Numerous case reports, systematic reviews, and warnings from regulatory bodies like Health Canada have established a link between the use of high-dose GTE supplements and a risk of rare, unpredictable, but potentially severe liver injury.³⁵ The risk appears to be idiosyncratic and may be higher in individuals on weight-loss diets (i.e., in a fasted or calorie-restricted state) and in those with a specific genetic marker (HLA-B*35:01).³⁵ The risk is associated with concentrated extracts, not with the consumption of brewed green tea.³⁵
• Common Side Effects: Milder side effects can include nausea, constipation, and abdominal discomfort.³⁸

Works cited

1. (PDF) The effect of Berberine on weight loss in order to prevent obesity: A systematic review, accessed September 29, 2025, https://www.researchgate.net/publication/340950457_The_effect_of_Berberine_on_weight_loss_in_order_to_prevent_obesity_A_systematic_review
2. Dose-response of Berberine on Hepatic Cytochromes P450 mRNA Expression and Activities in Mice - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3384737/
3. Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12160363/
4. Study Details | NCT03438292 | The Absorption of Bioactive Berberine in Human, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT03438292
5. Repeated administration of berberine inhibits cytochromes P450 in ..., accessed September 29, 2025, https://www.researchgate.net/publication/51598262_Repeated_administration_of_berberine_inhibits_cytochromes_P450_in_humans
6. Effects of berberine and tetrahydroberberine on CYP1A2 (A), CYP2A6 (B) - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Effects-of-berberine-and-tetrahydroberberine-on-CYP1A2-A-CYP2A6-B-CYP2B6-C_fig1_344612989
7. Effects of Berberis vulgaris, and its active constituent berberine on cytochrome P450: a review - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/39141022/
8. InnoSlim® | NuLiv Science - Ingredients Network, accessed September 29, 2025, https://www.ingredientsnetwork.com/innoslim-prod1271903.html
9. What is Innoslim®? - Gaia Herbs, accessed September 29, 2025, https://www.gaiaherbs.com/blogs/seeds-of-knowledge/innoslim
10. Toxicological Evaluation of a Mixture of Astragalus membranaceus and Panax notoginseng Root Extracts (InnoSlim®) - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6633876/
11. Astragalus membranaceus and Panax notoginseng saponins improves intestinal l-arginine absorption and protects against intestinal disorder in vivo - J-Stage, accessed September 29, 2025, https://www.jstage.jst.go.jp/article/fstr/29/2/29_FSTR-D-22-00116/_html/-char/ja
12. Apple cider vinegar side effects: What to know - Medical News Today, accessed September 29, 2025, https://www.medicalnewstoday.com/articles/324184
13. What are the health benefits of apple cider vinegar? - MD Anderson Cancer Center, accessed September 29, 2025, https://www.mdanderson.org/cancerwise/what-are-the-health-benefits-of-apple-cider-vinegar.h00-159696756.html
14. 7 Potential Side Effects of Apple Cider Vinegar - Everyday Health, accessed September 29, 2025, https://www.everydayhealth.com/diet-nutrition/potential-side-effects-apple-cider-vinegar/
15. 7 Potential Side Effects of Apple Cider Vinegar - Healthline, accessed September 29, 2025, https://www.healthline.com/nutrition/apple-cider-vinegar-side-effects
16. Apple cider vinegar for weight loss - Mayo Clinic, accessed September 29, 2025, https://www.mayoclinic.org/healthy-lifestyle/weight-loss/expert-answers/apple-cider-vinegar-for-weight-loss/faq-20058394
17. IGOB131, a novel seed extract of the West African plant Irvingia ..., accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2651880/
18. The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review of randomized controlled trials - NCBI, accessed September 29, 2025, https://www.ncbi.nlm.nih.gov/books/nbk132337/
19. The efficacy of Irvingia gabonensis supplementation in the ... - NCBI, accessed September 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK132337/
20. African Mango benefits, dosage, and side effects - Examine.com, accessed September 29, 2025, https://examine.com/supplements/african-mango/
21. IRVINGIA GABONENSIS: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed September 29, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-1252/irvingia-gabonensis
22. Irvingia gabonensis - Memorial Sloan Kettering Cancer Center, accessed September 29, 2025, https://www.mskcc.org/cancer-care/integrative-medicine/herbs/irvingia-gabonensis
23. What Is African Mango and Its Extract? Weight Loss and More - Healthline, accessed September 29, 2025, https://www.healthline.com/nutrition/african-mango
24. Effects of Chromium Picolinate on Food Intake and Satiety - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2753428/
25. Chromium picolinate supplementation for overweight or obese adults - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7433292/
26. Chromium - Special Subjects - MSD Manual Consumer Version, accessed September 29, 2025, https://www.msdmanuals.com/home/special-subjects/dietary-supplements-and-vitamins/chromium
27. CHROMIUM: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews, accessed September 29, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-932/chromium
28. Chromium picolinate Uses, Side Effects & Warnings - Drugs.com, accessed September 29, 2025, https://www.drugs.com/mtm/chromium-picolinate.html
29. Chromium Supplement: Health Benefits & Risks - WebMD, accessed September 29, 2025, https://www.webmd.com/diet/supplement-guide-chromium
30. Capsimax: A Weight Management Ingredient for Supplements, accessed September 29, 2025, https://omniactives.com/product/capsimax/
31. Study Details | NCT03489226 | Capsimax Effect on Metabolic Rate ..., accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT03489226
32. Capsaicin benefits, dosage, and side effects - Examine.com, accessed September 29, 2025, https://examine.com/supplements/capsaicin/
33. Tolerability of Capsaicinoids from Capsicum Extract in a Beadlet Form: A Pilot Study - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4811618/
34. Capsaicin: 4 Health Benefits, Uses, and Side Effects, accessed September 29, 2025, https://www.health.com/capsaicin-benefits-7643223
35. Hepatotoxicity of Green Tea Extract: Idiosyncratic or Indirect Drug ..., accessed September 29, 2025, https://www.xiahepublishing.com/2835-6357/FIM-2022-00034
36. Summary Safety Review - Green tea extract-containing natural health products - Assessing the potential risk of liver injury (hepatotoxicity) - Canada.ca, accessed September 29, 2025, https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/green-tea-extract-containing-natural-health-products-assessing-potential-risk-liver-injury.html
37. Hepatotoxicity from green tea: A review of the literature and two unpublished cases, accessed September 29, 2025, https://www.researchgate.net/publication/23986323_Hepatotoxicity_from_green_tea_A_review_of_the_literature_and_two_unpublished_cases
38. Green tea for weight loss and weight maintenance in overweight or obese adults - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8406948/
39. Gastrointestinal regulation of food intake - JCI, accessed September 29, 2025, https://www.jci.org/articles/view/30227
40. Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity—Therapeutic Implications - MDPI, accessed September 29, 2025, https://www.mdpi.com/2072-6643/13/4/1158
41. Proteins and Peptides from Food Sources with Effect on Satiety and Their Role as Anti-Obesity Agents: A Narrative Review - MDPI, accessed September 29, 2025, https://www.mdpi.com/2072-6643/16/20/3560
42. The biology of food noise - Numan, accessed September 29, 2025, https://www.numan.com/weight-loss/tips/biology-food-noise
43. Changes in ghrelin, GLP-1, and PYY levels after diet and exercise in obese individuals, accessed September 29, 2025, https://www.scielo.br/j/ramb/a/3jdNsFGw89qmVjYWcp8rsQf/?lang=en
44. Comparison of Postprandial Profiles of Ghrelin, Active GLP-1, and Total PYY to Meals Varying in Fat and Carbohydrate and Their Association With Hunger and the Phases of Satiety - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/236032208_Comparison_of_Postprandial_Profiles_of_Ghrelin_Active_GLP-1_and_Total_PYY_to_Meals_Varying_in_Fat_and_Carbohydrate_and_Their_Association_With_Hunger_and_the_Phases_of_Satiety
45. Current and emerging concepts on the role of peripheral signals in the control of food intake and development of obesity | British Journal of Nutrition, accessed September 29, 2025, https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/current-and-emerging-concepts-on-the-role-of-peripheral-signals-in-the-control-of-food-intake-and-development-of-obesity/33EF97CA321698769C49304C7ECB3380
46. Ghrelin, CCK, GLP-1, and PYY(3–36): Secretory Controls and ..., accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6151490/
47. Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity - PMC - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3286726/
48. Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11230893/
49. Gastrointestinal Hormones and Regulation of Gastric Emptying - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6615897/
50. Physical state of meal affects gastric emptying, cholecystokinin release and satiety | British Journal of Nutrition - Cambridge University Press, accessed September 29, 2025, https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/physical-state-of-meal-affects-gastric-emptying-cholecystokinin-release-and-satiety/A97189814BC39075A9220AD2A05B2051
51. Gastrointestinal hormones and regulation of gastric emptying - Mayo Clinic, accessed September 29, 2025, https://mayoclinic.elsevierpure.com/en/publications/gastrointestinal-hormones-and-regulation-of-gastric-emptying
52. Associations between postprandial insulin and blood glucose ..., accessed September 29, 2025, https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/associations-between-postprandial-insulin-and-blood-glucose-responses-appetite-sensations-and-energy-intake-in-normal-weight-and-overweight-individuals-a-metaanalysis-of-test-meal-studies/ACB46EA3F14946584DA4F420B2D27705
53. Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes - Frontiers, accessed September 29, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.661877/full
54. Postprandial glycaemic dips predict appetite and energy intake in healthy individuals - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7610681/
55. Associations between postprandial insulin and blood glucose responses, appetite sensations and energy intake in normal weight and overweight individuals: A meta-analysis of test meal studies - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/6309040_Associations_between_postprandial_insulin_and_blood_glucose_responses_appetite_sensations_and_energy_intake_in_normal_weight_and_overweight_individuals_A_meta-analysis_of_test_meal_studies
56. Food Order Has a Significant Impact on Postprandial Glucose and Insulin Levels - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4876745/
57. What Is “Food Noise”? Understanding Causes, Risks and When to Seek Help - Equip Health, accessed September 29, 2025, https://equip.health/articles/diet-culture-and-society/food-noise
58. Exacting Responses: Lack of Endocrine Cephalic Phase Responses Upon Oro-Sensory Exposure - Frontiers, accessed September 29, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00332/full
59. Neural and hormonal mechanisms of appetite regulation ... - Frontiers, accessed September 29, 2025, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1484827/full
60. Diet and cephalic phase insulin responses - ScienceDirect - DOI, accessed September 29, 2025, https://doi.org/10.1093%2Fajcn%2F42.5.991
61. Anticipatory physiological regulation in feeding biology: Cephalic phase responses, accessed September 29, 2025, https://www.researchgate.net/publication/5801661_Anticipatory_physiological_regulation_in_feeding_biology_Cephalic_phase_responses
62. The elusive cephalic phase insulin response: triggers, mechanisms, and functions, accessed September 29, 2025, https://journals.physiology.org/doi/abs/10.1152/physrev.00025.2022
63. Does berberine really help with weight loss? - Ohio State Health & Discovery, accessed September 29, 2025, https://health.osu.edu/wellness/exercise-and-nutrition/berberine-weight-loss
64. Lepticell Reviews and Complaints 2025, accessed September 29, 2025, https://music.usc.edu/wp-content/uploads/2025/09/Lepticellreevaluating-vbgBmye2.pdf
65. Berberine: A Powerful Supplement with Many Benefits - Healthline, accessed September 29, 2025, https://www.healthline.com/nutrition/berberine-powerful-supplement
66. (PDF) Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/392628584_Berberine_as_a_multi-target_therapeutic_agent_for_obesity_from_pharmacological_mechanisms_to_clinical_evidence
67. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways, accessed September 29, 2025, https://www.researchgate.net/publication/280327564_Berberine_induces_GLP-1_secretion_through_activation_of_bitter_taste_receptor_pathways
68. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/26206195/
69. Effects of Berberine in the Gastrointestinal Tract — A Review of Actions and Therapeutic Implications - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/265298185_Effects_of_Berberine_in_the_Gastrointestinal_Tract_-_A_Review_of_Actions_and_Therapeutic_Implications
70. Berberine moderates glucose metabolism through the GnRH-GLP-1 ..., accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/24912407/
71. Berberine for Appetite Suppressant and Prevention of Obesity - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7752296/
72. The effect of Berberine on weight loss in order to prevent obesity: A ..., accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/32353823/
73. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/32690176/
74. Hunger and Satiety Visual Analog Scales | Division of Cancer Control and Population Sciences (DCCPS), accessed September 29, 2025, https://cancercontrol.cancer.gov/brp/research/group-evaluated-measures/adopt/hunger-and-satiety
75. Hunger and Satiety Visual Analogue Scales (VAS) - UKnowledge, accessed September 29, 2025, https://uknowledge.uky.edu/cgi/viewcontent.cgi?filename=4&article=1017&context=foodsci_facpub&type=additional
76. Predictive Validity of Image-Based Motivation-to-Eat Visual Analogue Scales in Normal Weight Children and Adolescents Aged 9–14 Years - MDPI, accessed September 29, 2025, https://www.mdpi.com/2072-6643/14/3/636
77. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/10702749/
78. Hunger, Satiety, and Their Vulnerabilities - MDPI, accessed September 29, 2025, https://www.mdpi.com/2072-6643/16/17/3013
79. 4 Visual Analog Scales Widely Used in Food Intake Research - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/sual-Analog-Scales-Widely-Used-in-Food-Intake-Research_fig3_27476989
80. The effect of berberine supplementation on obesity indices: A dose– response meta-analysis and systematic review of randomized controlled trials | Request PDF - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/338983127_The_effect_of_berberine_supplementation_on_obesity_indices_A_dose-_response_meta-analysis_and_systematic_review_of_randomized_controlled_trials
81. Berberine-non-toxic natural molecule for weight loss - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/389891651_Berberine-non-toxic_natural_molecule_for_weight_loss
82. The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis - Frontiers, accessed September 29, 2025, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.1013055/full
83. Food Intake and Satiety Response after Medium-Chain Triglycerides Ingested as Solid or Liquid - Caldic Magistral, accessed September 29, 2025, https://magistralbr.caldic.com/storage/product-files/850782051.pdf
84. The Role of Protein in Regulating Ad Libitum Energy Intake in Humans | ClinicalTrials.gov, accessed September 29, 2025, https://clinicaltrials.gov/study/NCT02613065
85. Study Details | NCT01152333 | The Role of GLP-1 in Satiety Perception in Humans, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT01152333
86. Study Details | NCT05004584 | Validation of Appetite Method Visual Analogue Scales in Home-setting - ClinicalTrials.gov, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT05004584?term=vas%20or&viewType=Table&rank=2&checkSpell=
87. Study Details | NCT03330184 | Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level | ClinicalTrials.gov, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT03330184?term=BERBERINE&rank=5
88. Study Details | Energy Intake and Energy Deficit in Obese Adolescents | ClinicalTrials.gov, accessed September 29, 2025, https://clinicaltrials.gov/study/NCT03466359
89. Study Details | Effects of Excess Energy Intake on Metabolic Risk | ClinicalTrials.gov, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT00562393
90. Study Details | Treatment Benefits of Berberine Supplementation for Women With PCOS, accessed September 29, 2025, https://clinicaltrials.gov/study/NCT05480670?term=berberine&viewType=Table&rank=10
91. Berberine promotes glucagon-like peptide-1 (7–36) amide secretion in streptozotocin-induced diabetic rats in - Journal of Endocrinology, accessed September 29, 2025, https://joe.bioscientifica.com/view/journals/joe/200/2/159.xml
92. Berberine enhances the function of db/db mice islet β cell through GLP-1/GLP-1R/PKA signaling pathway in intestinal L cell and islet α cell - Frontiers, accessed September 29, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1228722/full
93. Berberine Metabolites Stimulate GLP-1 Secretion by Alleviating Oxidative Stress and Mitochondrial Dysfunction | The American Journal of Chinese Medicine - World Scientific Publishing, accessed September 29, 2025, https://www.worldscientific.com/doi/full/10.1142/S0192415X24500113
94. Metabolic Health and the Power of InnoSlim® - NuLiv Science, accessed September 29, 2025, https://nulivscience.com/metabolic-health-and-the-power-of-innoslim/
95. (PDF) Astragalus membranaceus and Panax notoginseng saponins improves intestinal L-arginine absorption and protects against intestinal disorder in vivo - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/365804232_Astragalus_membranaceus_and_Panax_notoginseng_saponins_improves_intestinal_L-arginine_absorption_and_protects_against_intestinal_disorder_in_vivo
96. Neuronal mechanisms of ginseng on antiobesity effects: implication of its synergistic benefits with physical exercise - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8743603/
97. Regulation of appetite-related neuropeptides by Panax ginseng: A novel approach for obesity treatment - Korea Science, accessed September 29, 2025, https://www.koreascience.kr/article/JAKO202219659893391.page
98. Ginseng and obesity - PMC - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5766689/
99. The Effect of a 2-Week Red Ginseng Supplementation on Food Efficiency and Energy Metabolism in Mice - MDPI, accessed September 29, 2025, https://www.mdpi.com/2072-6643/12/6/1726
100. Regulation of appetite-related neuropeptides by Panax ginseng: A novel approach for obesity treatment - PMC - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9270656/
101. Regulation of appetite-related neuropeptides by Panax ginseng: A novel approach for obesity treatment - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/35818423/
102. Astragalus membranaceus-Polysaccharides Ameliorates Obesity, Hepatic Steatosis, Neuroinflammation and Cognition Impairment without Affecting Amyloid Deposition in Metabolically Stressed APPswe/PS1dE9 Mice - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/29258283/
103. Research Breakdown on Astragalus - Examine.com, accessed September 29, 2025, https://examine.com/supplements/astragalus/research/
104. Study Details | NCT06827002 | Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults | ClinicalTrials.gov, accessed September 29, 2025, https://clinicaltrials.gov/study/NCT06827002
105. Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10450032/
106. Astragaloside IV Attenuates Orbital Inflammation in Graves' Orbitopathy Through Suppression of Autophagy - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/29127443/
107. Astragaloside-IV promotes autophagy via the Akt/mTOR pathway to improve cellular lipid deposition - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11030007/
108. Apple cider vinegar for weight management in Lebanese adolescents and young adults with overweight and obesity: a randomised, double-blind, placebo-controlled study, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11221284/
109. Apple cider vinegar for weight management in Lebanese adolescents and young adults with overweight and obesity: a randomised, double-blind, placebo-controlled study, accessed September 29, 2025, https://nutrition.bmj.com/content/early/2024/01/18/bmjnph-2023-000823
110. Effect of apple cider vinegar on delayed gastric emptying in patients ..., accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2245945/
111. (PDF) Apple cider vinegar for weight management in Lebanese adolescents and young adults with overweight and obesity: a randomised, double-blind, placebo-controlled study - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/378932592_Apple_cider_vinegar_for_weight_management_in_Lebanese_adolescents_and_young_adults_with_overweight_and_obesity_a_randomised_double-blind_placebo-controlled_study
112. Effects of Vinegar/Acetic Acid Intake on Appetite Measures and Energy Consumption: Systematic Review | Request PDF - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/361491312_Effects_of_VinegarAcetic_Acid_Intake_on_Appetite_Measures_and_Energy_Consumption_Systematic_Review
113. The Effects of Vinegar/Acetic Acid Intake on Appetite Measures and Energy Consumption: A Systematic Literature Review - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/361295496_The_Effects_of_VinegarAcetic_Acid_Intake_on_Appetite_Measures_and_Energy_Consumption_A_Systematic_Literature_Review
114. The Effects of Vinegar Acetic Acid Intake On Appetite Measures and Energy Consumption A Systematic Literature Review | PDF | Randomized Controlled Trial - Scribd, accessed September 29, 2025, https://www.scribd.com/document/734201586/The-Effects-of-Vinegar-Acetic-Acid-Intake-on-Appetite-Measures-and-Energy-Consumption-a-Systematic-Literature-Review
115. The Effects of Vinegar/Acetic Acid Intake on Appetite Measures and Energy Consumption: A Systematic Literature Review - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9193460/
116. Vinegar supplementation lowers glucose and insulin responses and increases satiety after a bread meal in healthy subjects - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/7729967_Vinegar_supplementation_lowers_glucose_and_insulin_responses_and_increases_satiety_after_a_bread_meal_in_healthy_subjects
117. Vinegar supplementation lowers glucose and insulin responses and ..., accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/16015276/
118. Influence of the tolerability of vinegar as an oral source of short-chain fatty acids on appetite control and food intake - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/23979220/
119. Effect of Apple Cider Vinegar Intake on Body Composition in Humans with Type 2 Diabetes and/or Overweight: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - MDPI, accessed September 29, 2025, https://www.mdpi.com/2072-6643/17/18/3000
120. Effect of Apple Cider Vinegar Intake on Body Composition in Humans with Type 2 Diabetes and/or Overweight: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | Request PDF - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/395682280_Effect_of_Apple_Cider_Vinegar_Intake_on_Body_Composition_in_Humans_with_Type_2_Diabetes_andor_Overweight_A_Systematic_Review_and_Meta-Analysis_of_Randomized_Controlled_Trials
121. Apple cider vinegar weight loss myth exposed: BMJ study retracted, accessed September 29, 2025, https://timesofindia.indiatimes.com/life-style/health-fitness/diet/apple-cider-vinegar-weight-loss-myth-exposed-bmj-study-retracted/articleshow/124111439.cms
122. RCT Results: Does Apple Cider Vinegar Improve Weight Loss Metrics in Adults with Overweight and Obesity? - The ObG Project, accessed September 29, 2025, https://www.obgproject.com/2024/04/15/rct-results-does-apple-cider-vinegar-improve-weight-loss-metrics-in-adults-with-overweight-and-obesity/
123. Effect of apple cider vinegar on delayed gastric emptying in people with type 1 diabetes mellitus. - Onderzoek met mensen, accessed September 29, 2025, https://onderzoekmetmensen.nl/en/node/23269/pdf
124. Effect of apple cider vinegar on delayed gastric emptying in patients with type 1 diabetes mellitus: a pilot study - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/18093343/
125. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/19254366/
126. Irvingia: Understanding the Risks of Leptin Resistance - - Life Extension, accessed September 29, 2025, https://www.lifeextension.com/magazine/2009/2/irvingia-understanding-the-risks-of-leptin-resistance
127. African Mango (Irvingia gabonensis) Extract for Weight Loss: A Systematic Review - Semantic Scholar, accessed September 29, 2025, https://pdfs.semanticscholar.org/abca/57cfa9c51eab5ba2e691efe2a4a10a04be54.pdf
128. Full article: The Effects of Irvingia gabonensis Seed Extract Supplementation on Anthropometric and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis - Taylor & Francis Online, accessed September 29, 2025, https://www.tandfonline.com/doi/full/10.1080/07315724.2019.1691956
129. Research Breakdown on African Mango - Examine.com, accessed September 29, 2025, https://examine.com/supplements/african-mango/research/
130. Chromium picolinate: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 29, 2025, https://go.drugbank.com/drugs/DB11255
131. Feasibility and Acceptability of Chromium Supplementation for Binge-Eating Disorder | Journal of Nutritional Medicine and Diet Care - ClinMed International Library, accessed September 29, 2025, https://clinmedjournals.org/articles/jnmdc/journal-of-nutritional-medicine-and-diet-care-jnmdc-2-010.php?jid=jnmdc
132. Effects of Chromium Picolinate on Food Intake and Satiety - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/23182439_Effects_of_Chromium_Picolinate_on_Food_Intake_and_Satiety
133. Effects of chromium picolinate on food intake and satiety - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/18715218/
134. A Double-blind, Randomized Pilot Trial of Chromium Picolinate for Binge Eating Disorder: Results of the Binge Eating and Chromium (BEACh) Study | Request PDF - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/237095949_A_Double-blind_Randomized_Pilot_Trial_of_Chromium_Picolinate_for_Binge_Eating_Disorder_Results_of_the_Binge_Eating_and_Chromium_BEACh_Study
135. Chromium picolinate supplementation for overweight or obese ..., accessed September 29, 2025, https://www.cochrane.org/evidence/CD010063_chromium-picolinate-supplementation-overweight-or-obese-people
136. A meta-analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/31115179/
137. (PDF) Effects of Chromium Picolinate Supplementation on Control of Metabolic Variables: A Systematic Review - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/308140424_Effects_of_Chromium_Picolinate_Supplementation_on_Control_of_Metabolic_Variables_A_Systematic_Review
138. Capsaicinoids and Capsinoids–A Potential Role for Weight Management? A Systematic Review of the Evidence | Request PDF - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/225063612_Capsaicinoids_and_Capsinoids-A_Potential_Role_for_Weight_Management_A_Systematic_Review_of_the_Evidence
139. Capsaicinoids and capsinoids. A potential role for weight ... - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/22634197/
140. The Effects of Capsaicin and Capsiate on Energy Balance: Critical Review and Meta-Analyses of Studies in Humans - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/22038945/
141. Dietary capsaicin and its anti-obesity potency: from mechanism to clinical implications - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5426284/
142. Capsaicinoids supplementation decreases percent body fat and fat mass: adjustment using covariates in a post hoc analysis - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6088424/
143. Acute administration of capsaicin increases resting energy expenditure in young obese subjects without affecting energy intake, appetite and circulating levels of orexigenic/anorexigenic peptides - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/323107868_Acute_administration_of_capsaicin_increases_resting_energy_expenditure_in_young_obese_subjects_without_affecting_energy_intake_appetite_and_circulating_levels_of_orexigenicanorexigenic_peptides
144. Capsimax Capsaicin Ingredient Increases Metabolic Rate in New Study - Nutritional Outlook, accessed September 29, 2025, https://www.nutritionaloutlook.com/view/capsimax-capsaicin-ingredient-increases-metabolic-rate-new-study
145. Capsimax increases metabolic rate in new clinical study - OmniActive Health Technologies, accessed September 29, 2025, https://omniactives.com/press-releases/new-study-on-omniactives-capsimax-reafirms-weight-management-support-benefit-trough-increased-metabolic-rate/
146. Omniactive's Capsimax Shown to Support Weight Management through Increased Metabolic Rate - Nutraceuticals World, accessed September 29, 2025, https://www.nutraceuticalsworld.com/breaking-news/omniactives-capsimax-shown-to-support-weight-management-through-increased-metabolic-rate/
147. Effect of Acute and Chronic Dietary Supplementation with Green Tea Catechins on Resting Metabolic Rate, Energy Expenditure and Respiratory Quotient: A Systematic Review - MDPI, accessed September 29, 2025, https://www.mdpi.com/2072-6643/13/2/644
148. (PDF) Effects of green tea on weight loss and weight maintenance. A ..., accessed September 29, 2025, https://www.researchgate.net/publication/26666169_Effects_of_green_tea_on_weight_loss_and_weight_maintenance_A_meta-analysis
149. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/26093535/
150. (−)-Epigallocatechin-3-gallate induces secretion of anorexigenic gut hormones - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4566026/
151. Effect of green tea or green tea extract consumption on body weight and body composition; systematic review and meta-analysis - NCBI, accessed September 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK231811/
152. Effects of Green Tea Extract on Insulin Resistance and Glucagon ..., accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3948786/
153. Effects of green tea extract on insulin resistance and glucagon-like peptide 1 in patients with type 2 diabetes and lipid abnormalities: a randomized, double-blinded, and placebo-controlled trial - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/24614112/